313 related articles for article (PubMed ID: 27593928)
41. Epigenetics and approaches to targeted epigenetic therapy in acute myeloid leukemia.
Wouters BJ; Delwel R
Blood; 2016 Jan; 127(1):42-52. PubMed ID: 26660432
[TBL] [Abstract][Full Text] [Related]
42. The DNA damage-independent ATM signalling maintains CBP/DOT1L axis in MLL rearranged acute myeloid leukaemia.
Wang G; Zhang W; Ren J; Zeng Y; Dang X; Tian X; Yu W; Li Z; Ma Y; Yang P; Lu J; Zheng J; Lu B; Xu J; Liang A
Oncogene; 2024 Jun; 43(25):1900-1916. PubMed ID: 38671157
[TBL] [Abstract][Full Text] [Related]
43. DNA Methylation Targeting: The DNMT/HMT Crosstalk Challenge.
Castillo-Aguilera O; Depreux P; Halby L; Arimondo PB; Goossens L
Biomolecules; 2017 Jan; 7(1):. PubMed ID: 28067760
[TBL] [Abstract][Full Text] [Related]
44. Role of histone methylation in skin cancers: Histone methylation-modifying enzymes as a new class of targets for skin cancer treatment.
Sutopo NC; Kim JH; Cho JY
Biochim Biophys Acta Rev Cancer; 2023 May; 1878(3):188865. PubMed ID: 36841366
[TBL] [Abstract][Full Text] [Related]
45. The role of histone demethylases in cancer therapy.
Hoffmann I; Roatsch M; Schmitt ML; Carlino L; Pippel M; Sippl W; Jung M
Mol Oncol; 2012 Dec; 6(6):683-703. PubMed ID: 22902149
[TBL] [Abstract][Full Text] [Related]
46. [Chemical targeting of DNA and histone methylation in cancer: Novelties, hopes and promises].
Bon C; Erdmann D; Halby L; Arimondo PB
Bull Cancer; 2019 Oct; 106(10):823-833. PubMed ID: 31522746
[No Abstract] [Full Text] [Related]
47. Histone methyltransferase MLL1 regulates MDR1 transcription and chemoresistance.
Huo H; Magro PG; Pietsch EC; Patel BB; Scotto KW
Cancer Res; 2010 Nov; 70(21):8726-35. PubMed ID: 20861184
[TBL] [Abstract][Full Text] [Related]
48. Targeting protein lysine methylation and demethylation in cancers.
He Y; Korboukh I; Jin J; Huang J
Acta Biochim Biophys Sin (Shanghai); 2012 Jan; 44(1):70-9. PubMed ID: 22194015
[TBL] [Abstract][Full Text] [Related]
49. Epigenetic Therapy in Acute Myeloid Leukemia: Current and Future Directions.
Kim TK; Gore SD; Zeidan AM
Semin Hematol; 2015 Jul; 52(3):172-83. PubMed ID: 26111464
[TBL] [Abstract][Full Text] [Related]
50. Targeting histone-modifications in Alzheimer's disease. What is the evidence that this is a promising therapeutic avenue?
Fischer A
Neuropharmacology; 2014 May; 80():95-102. PubMed ID: 24486385
[TBL] [Abstract][Full Text] [Related]
51. The emerging roles of histone demethylases in cancers.
Tong D; Tang Y; Zhong P
Cancer Metastasis Rev; 2024 Jun; 43(2):795-821. PubMed ID: 38227150
[TBL] [Abstract][Full Text] [Related]
52. Epigenetic targeting in pancreatic cancer.
van Kampen JG; Marijnissen-van Zanten MA; Simmer F; van der Graaf WT; Ligtenberg MJ; Nagtegaal ID
Cancer Treat Rev; 2014 Jun; 40(5):656-64. PubMed ID: 24433955
[TBL] [Abstract][Full Text] [Related]
53. Insights into the epigenetic mechanisms involving histone lysine methylation and demethylation in ischemia induced damage and repair has therapeutic implication.
Chakravarty S; Jhelum P; Bhat UA; Rajan WD; Maitra S; Pathak SS; Patel AB; Kumar A
Biochim Biophys Acta Mol Basis Dis; 2017 Jan; 1863(1):152-164. PubMed ID: 27664837
[TBL] [Abstract][Full Text] [Related]
54. Improved therapeutic effect against leukemia by a combination of the histone methyltransferase inhibitor chaetocin and the histone deacetylase inhibitor trichostatin A.
Tran HT; Kim HN; Lee IK; Nguyen-Pham TN; Ahn JS; Kim YK; Lee JJ; Park KS; Kook H; Kim HJ
J Korean Med Sci; 2013 Feb; 28(2):237-46. PubMed ID: 23400519
[TBL] [Abstract][Full Text] [Related]
55. Rational Targeting of Cooperating Layers of the Epigenome Yields Enhanced Therapeutic Efficacy against AML.
Duy C; Teater M; Garrett-Bakelman FE; Lee TC; Meydan C; Glass JL; Li M; Hellmuth JC; Mohammad HP; Smitheman KN; Shih AH; Abdel-Wahab O; Tallman MS; Guzman ML; Muench D; Grimes HL; Roboz GJ; Kruger RG; Creasy CL; Paietta EM; Levine RL; Carroll M; Melnick AM
Cancer Discov; 2019 Jul; 9(7):872-889. PubMed ID: 31076479
[TBL] [Abstract][Full Text] [Related]
56. Mutations in epigenetic modifiers in acute myeloid leukemia and their clinical utility.
Hou HA; Tien HF
Expert Rev Hematol; 2016 May; 9(5):447-69. PubMed ID: 26789100
[TBL] [Abstract][Full Text] [Related]
57. Histone methyltransferase inhibitors: novel epigenetic agents for cancer treatment.
Zagni C; Chiacchio U; Rescifina A
Curr Med Chem; 2013; 20(2):167-85. PubMed ID: 23210854
[TBL] [Abstract][Full Text] [Related]
58. [Development of novel epigenetic molecular-targeting agents].
Sowa Y; Sakai T
Nihon Rinsho; 2015 Aug; 73(8):1263-7. PubMed ID: 26281676
[TBL] [Abstract][Full Text] [Related]
59. The role of histone modifications and variants in regulating gene expression in breast cancer.
Dalvai M; Bystricky K
J Mammary Gland Biol Neoplasia; 2010 Mar; 15(1):19-33. PubMed ID: 20131086
[TBL] [Abstract][Full Text] [Related]
60. Epigenetic regulatory mutations and epigenetic therapy for multiple myeloma.
Dupéré-Richer D; Licht JD
Curr Opin Hematol; 2017 Jul; 24(4):336-344. PubMed ID: 28441149
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
